COMP <GO>
PRME vs CGEM // REVENUE GROWTH (YOY)
Prime Medicine Inc. (NASDAQ) VS. Cullinan Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PRME 3
— CGEM 1
■ METRIC PARITY
LAST: $5.24 (-2.24%) • MKT CAP: $950.4M
revenue-growth
55.30%
LAST: $15.45 (-0.71%) • MKT CAP: $994.3M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRME VS. CGEM)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRME | CGEM | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -17.58% | -17.68% | +0.10 | PRME | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 55.30% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | PRME | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.5 | 45.3 | +16.22 | PRME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $950.4M | $994.3M | -$43.9M | CGEM | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRME REV | CGEM REV | PRME GROSS % | CGEM GROSS % | PRME FCF | CGEM FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.6M | $0 | — | — | -$167.1M | -$175.8M |
| FY 2024 | $3.0M | $0 | — | — | -$130.2M | -$145.3M |
| FY 2023 | $0 | $0 | — | — | -$165.4M | -$134.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRME // BETA —
CGEM // BETA —